Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Unique Huntington's study moves forward

10.08.2006
Those at risk who decline gene test provide basis for look at early symptoms

Doctors have completed the first step of a unique medical research study, evaluating 1,001 individuals at risk of developing Huntington's disease who do not know – nor do they want to know – whether they carry the genetic defect that causes the condition.

An international team led by neurologist Ira Shoulson, M.D., of the University of Rochester Medical Center is trying to identify the earliest signs of the onset of the disease. The information will help clinicians design better studies of new drugs aimed at alleviating or postponing illness. It also helps researchers understand how patients evaluate potentially life-changing knowledge now available to patients through means such as genetic testing.

Shoulson and colleagues from the Huntington Study Group reported their progress on the study known as PHAROS, or Prospective Huntington At Risk Observational Study, in the July issue of the Archives of Neurology.

While the gene that causes the disease is known and can be identified through a blood test, fewer than one in 10 adults at risk for developing the disease have chosen to be tested. People at risk but who have not taken the test have a 50/50 chance of developing the disease. This at-risk group offers physicians a unique opportunity to witness the earliest signs of the disease, before anyone knows whether a person actually has the gene for Huntington's or not.

In the PHAROS study, one of the largest Huntington's studies ever undertaken, 1,001 healthy people between the ages of 26 to 55 who had at least one parent with the disease have stepped forward to participate. Patients, doctors and nurses from 43 hospitals and medical centers around North America, including Rochester, are taking part.

At enrollment in PHAROS, participants provide a blood sample to analyze whether or not they harbor the Huntington's gene, though neither they, the researchers, nor their physicians will ever be told the results of the individual analyses. Participants are being evaluated once every nine months for anywhere from four to 10 years.

"The at-risk individuals who are participating in PHAROS do not know if they have inherited the gene responsible for Huntington's disease or if they will ever even develop this serious disease," said Shoulson, who chairs the Huntington Study Group. "The enthusiasm and commitment of these individuals to participate in this type of long-term research is gratifying. We expect that the knowledge from this observational study will be put to good use when we begin clinical trials to delay the onset of Huntington's disease."

Huntington's is an inherited disorder that affects about 30,000 people in North America; another 150,000 people or so may have the gene that causes the disease. The defective gene, a sort of genetic stutter, leads to the destruction of brain cells, causing involuntary movements, cognitive problems, and often psychological problems like depression and paranoia. The disease usually strikes in young- to mid-adulthood, in a patient's 30s or 40s.

The study is relevant for many physicians and patients who have increasing access to information about the specific genetic causes of many diseases, even for conditions like Huntington's for which there is no cure or approved treatment. The issues these patients face portend concerns that nearly everyone will confront eventually, as researchers ferret out the genes that predispose some people to heart trouble, high blood pressure, Alzheimer's and Parkinson's diseases, stroke, and other diseases. People at risk for Huntington's disease today present a unique opportunity for researchers to examine the psychosocial, ethical, and practical issues faced by people who have chosen not to know whether they will develop a serious disease or not.

"The experience from PHAROS also informs us how persons at high risk to develop a disabling genetic disease deal with lingering uncertainties about their future health and complex choices about their participation in research," said Shoulson, part of a Rochester team that treats Huntington's patients from more than 200 families.

The group that has signed up is remarkably healthy, with more than 99 out of 100 participants either showing no detectable signs of Huntington's or a symptom not necessarily tied to the disease. Nearly all participants are employed, with the majority in professional or managerial jobs; overall the group of participants is highly educated, with nearly half having at least four years of education after high school. For reasons that researchers don't understand, more than twice as many women as men, 689 compared to 312, have signed up for the study.

Tom Rickey | EurekAlert!
Further information:
http://www.urmc.rochester.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>